文献速递生殖医学妇科

人类生殖系基因组编辑的性别禁令影响

The implications of the gender-based prohibitions relating to human germline genome editing in the Human Fertilisation and Embryology Act.
PubMed 文献 · Reprod Biomed Online · 2020-11-20

本研究探讨2008年修订的《人类受精与胚胎学法案》中基于性别的生殖系基因组编辑禁令的影响。通过混合方法研究,发现这些禁令削弱了防止编辑基因组妊娠的立法意图,并可能随技术发展而问题加剧。结论建议修订法案以避免性别歧视并防止规避行为。

要点

  • HFE法案的性别禁令削弱防止编辑基因组妊娠的意图
  • 禁令可能随基因编辑技术发展而日益问题化
  • 建议修订法案以消除性别歧视并防止规避

核心结论

  • HFE法案应修订以避免性别歧视,并防止基于性别的禁令被规避用于生殖系基因组编辑。

主要发现

  • HFE法案中基于性别的禁令削弱了其防止生殖系细胞被修改后导致妊娠和可能出生编辑基因组个体的意图。
  • 随着基因组编辑技术发展和社会进步寻求消除性别期望和二元论,这一弱点可能日益问题化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What are the implications of the gender-based prohibitions relating to human germline genome editing (hGGE) in the Human Fertilisation and Embryology (HFE) Act 1990, as amended in 2008? DESIGN: A three-phase primary research design consisting of a mixed-methods online public survey of 521 UK citizens aged 16-82 years, 13 semi-structured interviews with experts and professionals involved in the future of hGGE, and structured interviews with 21 people affected by genetic conditions. The research was conducted between March 2018 and October 2019. RESULTS: Gender-based prohibitions in the HFE Act weaken its intent to prevent germline cells that have been altered from resulting in a pregnancy and the possible birth of people with edited genomes. This weakness could become increasingly problematic as genome editing technologies develop and social advances seek to eradicate gendered expectations and gendered binaries. CONCLUSION: The HFE Act should be amended to avoid gender-based discrimination and the potential gender-based prohibitions have to circumvent germline genome editing being used before the technology is considered safe enough to prevent disease.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Kaur A. The implications of the gender-based prohibitions relating to human germline genome editing in the Human Fertilisation and Embryology Act. Reprod Biomed Online. 2020. PMID: 33293222. doi:10.1016/j.rbmo.2020.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。